AllianceBernstein’s Janux Therapeutics JANX Stock Holding History

AllianceBernstein’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$847K	Buy	60,960 +25,370	+71%	+$368K	﹤0.01%	2464
2026 Q1	$491K	Hold	35,590	–	–	﹤0.01%	2643
2025 Q4	$491K	Hold	35,590	–	–	﹤0.01%	2666
2025 Q3	$870K	Hold	35,590	–	–	﹤0.01%	2409
2025 Q2	$822K	Sell	35,590 -23,786	-40%	-$627K	﹤0.01%	2397
2025 Q1	$1.6M	Buy	59,376 +31,736	+115%	+$1.2M	﹤0.01%	2011
2024 Q4	$1.48M	Hold	27,640	–	–	﹤0.01%	2120
2024 Q3	$1.26M	Sell	27,640 -1,600	-5%	-$69.6K	﹤0.01%	2207
2024 Q2	$1.22M	Buy	29,240 +5,690	+24%	+$267K	﹤0.01%	2205
2024 Q1	$887K	Buy	23,550 +6,180	+36%	+$135K	﹤0.01%	2328
2023 Q4	$186K	Buy	17,370 +510	+3%	+$4.41K	﹤0.01%	2992
2023 Q3	$170K	Buy	16,860 +1,830	+12%	+$21.1K	﹤0.01%	2992
2023 Q2	$178K	Buy	+15,030	New	+$201K	﹤0.01%	3007

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AllianceBernstein's JANX Position: Q2 2026 in Review

AllianceBernstein increased its Janux Therapeutics (JANX) stake by 71% in Q2 2026, buying an estimated $368K and bringing the position to 60,960 shares worth $847K. The position accounts for ﹤0.01% of the portfolio, ranked #2464.

AllianceBernstein first reported a position in JANX in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.6M in Q1 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

AllianceBernstein held 60,960 shares of Janux Therapeutics worth $847K as of Q2 2026.
AllianceBernstein bought 25,370 Janux Therapeutics shares in Q2 2026, an estimated $368K.
Janux Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2464 holding.
AllianceBernstein first reported a position in Janux Therapeutics in Q2 2023 and has held it in 13 quarters since.
AllianceBernstein's Janux Therapeutics position peaked at $1.6M in Q1 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.